Blastomycosis affects multiple mammals, including people, which makes it a critical fungal infection. This condition is caused by the fungus of the Blastomyces genus which is found in the environment as it is caused. Our company would be able to support you in developing pharmaceuticals for blastomycosis by providing a seamlessly tailored range of services intended for specific research scientists.
Overview of Blastomycosis
Blastomycosis is an infection caused by Blastomyces dermatitidis which is a dimorphic fungus. Now more than ever, there has been an increased understanding of the genetic and geographical diversity that exists within the dimensional pathogens. It has been reported that Blastomyces dermatitidis and the cryptic species Blastomyces gilchristii are found in some regions of North America, while atypical cases are associated with: Blastomyces helicus found in the western United States; and Blastomyces percursus in Africa.
Fig.1 Map of the estimated distribution of Blastomyces. (Pullen, M. F., et al., 2022)
Pathogenesis of Blastomycosis
As mentioned above blastomycosis is a disease that is acquired as a result of inhaling fungal spores found in the environment. The spores in the lungs are turned into pathogenic yeast form and spread through the blood into different body parts. The most prominent and classic primary complication of Blastomycosis is in the lungs, individuals indicated there were mild self-limiting infections to severe life threats including adult respiratory distress syndrome.
Fig.2 Characteristic Blastomyces microscopy. (Pullen, M. F., et al., 2022)
Vaccine and Therapeutics Development for Blastomycosis
Vaccine Development
Blastomyces dermatitidis proteins such as BAD-1 have been a focal point of interest for a wide repertoire of approaches ranging from subunit vaccines, and live-attenuated vaccines to DNA vaccines.
Therapeutics Development
The management of blastomycosis has focused on medication therapy involving antifungals of the azole class such as voriconazole and itraconazole as well as amphotericin B.
Our Services
We have robust capabilities that include the amalgamation of all research services affiliated with the blastomycosis disease alongside providing access to cutting-edge technology, an amalgamated service platform that includes disease models, vaccines, and a dedicated therapeutic development team and experts for the advancement of the field.
Therapeutic Development Services of Blastomycosis
Vaccine Development of Blastomycosis
Infectious Disease Models
Our company offers a range of blastomycosis models development services that strive to provide a clearer understanding of blastomycosis pathogenesis, and host-pathogen interrelations, and ensure the formulation of optimal diagnostic, preventive, and therapeutic protocols.
Pathogen Infection Models
Animals can be infected with Blastomyces dermatitidis spores or yeast cells, either through intranasal, intratracheal, or intravenous routes.
Optional Models: Mouse model of Blastomyces dermatitidis infection, etc.
Why Choose Us
We take pride in the fact that our services support research translates into that can further be implemented into a therapeutic of blastomycosis, since the tools and the infrastructure that researchers require are offered, and we stand out specifically for our innovation and aspirational approach which puts us at the cutting edge of the blastomycosis research.
If you are interested in our service, do not hesitate to reach out to us for additional insights and detailed quotations about the specialized services we provide.
Reference
- Pullen, Matthew F et al. "Blastomycosis-Some Progress but Still Much to Learn." Journal of fungi (Basel, Switzerland) 8.8 (2022): 824.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
